Haier Biomedical Expands European Strategy and Product Portfolio at Rome Summit

Haier Biomedical announced in a press release that it hosted its European Partner Summit in Rome under the theme “Advancing Together – Sharing the Future of Biomedical Innovation.” The event gathered 37 regional partners and industry leaders from 23 countries to discuss the company’s long-term commitment to Europe and to present an expanded laboratory solutions portfolio as part of its strategic upgrade.

At the summit, Enrique Wang, Global Market Director, reaffirmed the company’s goal to generate over 50% of its global revenue from international markets by 2027 and to achieve more than half of its revenue from non-refrigeration business lines by 2028. The European strategy focuses on scenario-based, application-driven solutions and deeper localization to align with regional standards and needs.

The company highlighted several new products, including the Plasma Apheresis System XJ-III, which recently obtained EU MDR certification. Other key products such as CO₂ incubators, centrifuges, biosafety cabinets, and cold storage systems continue to gain traction in Europe due to their compliance with regional energy and safety standards.

Automation and intelligent blood management were identified as growth areas. The company’s automated biobank solutions combine RFID-enabled ultra-low temperature storage and modular automation to improve sample traceability and efficiency. Its U-Blood system introduces real-time connected blood management to reduce wastage and enhance supply chain transparency.

Haier Biomedical reported 2025 revenue exceeding RMB 2.3 billion, with international sales contributing 36% of the total. The company plans continued investment in local service and product expertise to strengthen its European presence and support growth across laboratories, hospitals, and life science institutions.